Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Non-Current Assets (2020 - 2025)

Gain Therapeutics has reported Non-Current Assets over the past 6 years, most recently at $454412.0 for Q3 2025.

  • Quarterly results put Non-Current Assets at $454412.0 for Q3 2025, down 27.22% from a year ago — trailing twelve months through Sep 2025 was $454412.0 (down 27.22% YoY), and the annual figure for FY2024 was $457602.0, down 44.9%.
  • Non-Current Assets for Q3 2025 was $454412.0 at Gain Therapeutics, down from $527277.0 in the prior quarter.
  • Over the last five years, Non-Current Assets for GANX hit a ceiling of $6.1 million in Q2 2022 and a floor of $454412.0 in Q3 2025.
  • Median Non-Current Assets over the past 5 years was $855891.0 (2023), compared with a mean of $1.4 million.
  • Biggest five-year swings in Non-Current Assets: soared 495.07% in 2022 and later crashed 84.28% in 2023.
  • Gain Therapeutics' Non-Current Assets stood at $1.3 million in 2021, then skyrocketed by 138.17% to $3.0 million in 2022, then crashed by 72.39% to $830463.0 in 2023, then tumbled by 44.9% to $457602.0 in 2024, then decreased by 0.7% to $454412.0 in 2025.
  • The last three reported values for Non-Current Assets were $454412.0 (Q3 2025), $527277.0 (Q2 2025), and $472647.0 (Q1 2025) per Business Quant data.